摘要
目的:探讨帕利哌酮缓释片与利培酮对精神分裂症阴性症状的疗效和安全性。方法:分别使用帕利哌酮缓释片与利培酮对60例以阴性症状为主精神分裂症患者治疗8周,用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)分别在治疗前、治疗第4周和第8周末评定疗效和安全性。结果:研究组显效率和有效率分别为63.3%和80%,对照组分别为60%和76.7%,两组比较,差异无统计学意义(P>0.05)。两组PANSS评分治疗后均较治疗前明显下降(P<0.05),研究组阴性症状因子分在治疗4周和8周时分别为(15.40±1.04)分和(12.80±0.76)分,显著低于对照组的(20.60±1.13)分和(18.10±0.71)分,两组比较,差异有统计学意义(P<0.05);研究组第8周末PANSS总分为(42.90±0.84)分,低于对照组的(44.80±0.61)分,有统计学差异(P<0.05)。研究组的不良反应以锥体外系反应和嗜睡为主,对照组以锥体外系反应和失眠、体重增加和视物模糊为主,两组的不良反应相当,均未见严重不良反应。结论:帕利哌酮缓释片是一种安全有效的抗精神病药,能够显著改善精神分裂症的阴性症状。
AIM： To study the efficacy and safety of paliperidone extended-release tablet （Paliperidone-ER） and Risperidone on negative symptoms of schizophrenia. METHODS： Sixty cases of schizophrenics with prominent negative symptoms were randomly divided into study group（n=30）and control group（n=30）. Thirty cases of Paliperidone-ER treated patients were compared with thirty cases of Risperidone treated patients. The duration of study was 8 weeks. The therapeutic efficacy and safety were assessed with the PANSS and TESS, respectively. RESULTS：The significantly effective rate and effective rate of Paliperidone-ER were 63.3% and 80%, and of Risperidone were 60% and 76.7% respectively, and there were no significant differences between two groups （P 〉 0.05 ）. Paliperidone-ER group showed lower negative symptom score at the fourth week（15.40±1.04） and at the eighth week（12.80±0.76） than Risperidone group, although the scores decreased at thefourth week （20.60 ±1.13） and at the eighth week （18. 10 ±0. 71）. There were significant differences between two groups （ P 〉 0.05 ）. At the eighth week , the full score of PANSS of study group was （42.90±0.84）, the full score of PANSS of control group was（44.80±0.61）. There were significant differences between two groups（ P 〉 0. 05 ）. The TESS of study group were EPS and drowsiness. The TESS of control group were EPS,wakefulness,increase of weight and faintness eyesight. There were no severe adverse effects in two groups. CONCLUSION： Paliperidone-ER is an effective and safe antipsychotic drug with more showing significant improvement compared with Risperidone in nega-ive symptoms.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2011年第7期819-822,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
精神分裂症
帕利哌酮缓释片
利培酮片
阴性症状
Schizophrenia
Paliperidone extended-release tablet
Risperidone
Negative symptom
